VTRS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.19
Percentage change -1.48	%

Peers: PFE MRK BMY JNJ ABBV GSK LLY AMGN SNY NVS

| Held by: VTI VOO VO SPY IVV RSP VTV XLV VOE SPYD

Scroll to Statements

Index	S&P 500	P/E	-	EPS (ttm)	-0.74	Insider Own	2.44%	Shs Outstand	1.19B	Perf Week	-0.71%
Market Cap	14.85B	Forward P/E	4.74	EPS next Y	2.66	Insider Trans	-3.23%	Shs Float	1.16B	Perf Month	-2.85%
Income	-883.30M	PEG	-	EPS next Q	0.58	Inst Own	79.61%	Short Float	1.77%	Perf Quarter	6.94%
Sales	15.03B	P/S	0.99	EPS this Y	-8.42%	Inst Trans	-2.20%	Short Ratio	2.68	Perf Half Y	24.19%
Book/sh	16.58	P/B	0.76	EPS next Y	-0.93%	ROA	-1.89%	Short Interest	20.60M	Perf Year	24.68%
Cash/sh	1.68	P/C	7.52	EPS next 5Y	-3.41%	ROE	-4.35%	52W Range	9.82 - 13.62	Perf YTD	16.62%
Dividend Est.	-	P/FCF	7.62	EPS past 5Y	-41.87%	ROI	-2.58%	52W High	-7.25%	Beta	0.95
Dividend TTM	0.48 (3.80%)	Quick Ratio	0.88	Sales past 5Y	7.93%	Gross Margin	40.92%	52W Low	28.63%	ATR (14)	0.32
Dividend Ex-Date	Nov 22, 2024	Current Ratio	1.43	EPS Y/Y TTM	-148.59%	Oper. Margin	9.48%	RSI (14)	47.73	Volatility	2.88% 2.37%
Employees	38000	Debt/Eq	0.81	Sales Y/Y TTM	-2.55%	Profit Margin	-5.88%	Recom	3.09	Target Price	13.17
Option/Short	Yes / Yes	LT Debt/Eq	0.73	EPS Q/Q	-71.23%	Payout	1059.60%	Rel Volume	0.89	Prev Close	12.82
Sales Surprise	0.96%	EPS Surprise	10.82%	Sales Q/Q	-4.30%	Earnings	Nov 07 BMO	Avg Volume	7.69M	Price	12.63
SMA20	-2.75%	SMA50	2.62%	SMA200	8.66%	Trades		Volume	6,871,793	Change	-1.48%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-19-24	Resumed	Jefferies	Buy	$15
Oct-23-23	Downgrade	BofA Securities	Neutral → Underperform	$13 → $9
Jun-23-23	Downgrade	Barclays	Equal Weight → Underweight	$11
Apr-24-23	Downgrade	Barclays	Overweight → Equal Weight	$11
Feb-17-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$16 → $14
Jan-27-23	Upgrade	Jefferies	Hold → Buy	$13 → $15
Nov-10-22	Upgrade	UBS	Sell → Neutral	$9 → $12
Nov-08-22	Upgrade	Piper Sandler	Underweight → Neutral	$10
Oct-21-22	Resumed	Jefferies	Hold	$11
Jun-14-22	Initiated	UBS	Sell	$9
May-10-22	Downgrade	Piper Sandler	Neutral → Underweight	$10
Mar-01-22	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $13
Jun-15-21	Initiated	Citigroup	Neutral	$16
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$24
Mar-08-21	Downgrade	Goldman	Buy → Neutral	$20 → $15
Mar-02-21	Downgrade	JP Morgan	Overweight → Neutral	$21 → $18
Feb-26-21	Downgrade	Wolfe Research	Outperform → Peer Perform	$17
Jan-05-21	Initiated	Argus	Hold
Dec-14-20	Initiated	Bernstein	Mkt Perform	$21

Show Previous Ratings

Dec-02-24 08:30AM	Mapi Pharma is Seeking New Depot Product Partnerships (GlobeNewswire)
Nov-21-24 08:51AM	Viatris fined in Morocco over merger notification, sources say (Reuters)
Nov-11-24 11:01AM	ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m (Pharmaceutical Technology)
Nov-08-24 02:14AM	Viatris Inc (VTRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ... (GuruFocus.com)
Nov-07-24 05:02PM	S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark Rate (Investopedia) +13.52%
04:46PM	Loading…
04:46PM	Analyst Report: Viatris Inc. (Morningstar Research)
09:30AM	Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:25AM	Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:27AM	Viatris: Q3 Earnings Snapshot (Associated Press Finance)
06:59AM	Viatris Reports Third Quarter Financial Results for 2024 (PR Newswire)
Nov-05-24 06:59AM	Viatris Announces Third Quarter 2024 Dividend (PR Newswire)
Nov-04-24 09:16AM	Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Oct-29-24 12:00PM	Viatris Named to Forbes' World's Top Companies for Women 2024 List (PR Newswire)
09:00AM	Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference (PR Newswire)
02:00AM	Idorsia announces financial results for the first nine months of 2024 (GlobeNewswire)
07:15AM	Loading…
Oct-17-24 07:15AM	Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe (BioPharma Dive)
05:55AM	Lexicon partners Viatris for global expansion of sotagliflozin (Pharmaceutical Technology)
Oct-16-24 04:35PM	Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe (GlobeNewswire)
04:34PM	Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe (PR Newswire)
Oct-15-24 06:27PM	Viatris Settles Lawsuit, Avoids Antitrust Charges, and Advances Effexor Study (GuruFocus.com)
Oct-14-24 01:40PM	Viatris Inc. (VTRS): David Einhorns Top Stock Pick (Insider Monkey)
Oct-12-24 11:16AM	Viatris Inc. (VTRS): A Strategic Shift in Healthcare Investments (Insider Monkey)
Oct-10-24 10:15AM	Viatris 2023 Sustainability Report: Reducing Packaging Material (ACCESSWIRE)
Oct-09-24 05:38PM	Viatris Inc (VTRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations (GuruFocus.com)
06:59AM	Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR in Japanese Adults with Generalized Anxiety Disorder (GAD) (PR Newswire)
Oct-08-24 03:40PM	Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row (ACCESSWIRE)
11:23AM	Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20? (Insider Monkey)
Oct-07-24 04:15PM	Viatris 2023 Sustainability Report: Expanding Contractor Training (ACCESSWIRE)
Oct-01-24 10:50AM	Is Viatris Inc. (VTRS) the Best Stock Under $15 To Buy Now? (Insider Monkey)
Sep-30-24 06:59AM	Viatris launches (Pr)Viagra® ODF in Canada: a new oral dissolving film form of the erectile dysfunction treatment (PR Newswire)
01:25PM	Loading…
Sep-19-24 01:25PM	In Europe, Packaging Site Takes Flight as a Bird-Friendly Workplace (ACCESSWIRE)
11:05AM	Viatris 2023 Sustainability Report: Health and Safety in the Workplace (ACCESSWIRE)
Sep-18-24 11:30AM	Viatris Announces the Pricing Terms of Maximum Tender Offer (PR Newswire)
Sep-17-24 08:45PM	Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer (PR Newswire)
Sep-16-24 04:30PM	Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024 (PR Newswire)
10:45AM	From Opposite Ends of the Earth, the Same Story: Women Push for Positive Change (ACCESSWIRE)
09:04AM	Do Options Traders Know Something About Viatris (VTRS) Stock We Don't? (Zacks)
Sep-12-24 10:15AM	Viatris 2023 Sustainability Report: Advocating for Patients (ACCESSWIRE)
Sep-10-24 07:00PM	Viatris Announces Expiration and Results of Any and All Cash Tender Offers (PR Newswire)
11:40AM	Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers (PR Newswire)
Sep-09-24 10:15AM	Viatris 2023 Sustainability Report: Breaking Down Systemic Barriers To Access Through Policy Engagement (ACCESSWIRE)
Sep-04-24 11:55AM	Viatris 2023 Sustainability Report: Continued Innovation for Infectious Disease (ACCESSWIRE)
03:30AM	Viatris Announces Cash Tender Offers for Certain Outstanding Notes (PR Newswire)
Sep-02-24 06:33AM	ESC 2024: Single-pill hypertension combo delivers positive results (Pharmaceutical Technology)
Aug-23-24 06:59AM	Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress (PR Newswire)
Aug-20-24 05:30AM	3 Top Value Stocks to Buy Right Now (Motley Fool)
Aug-09-24 09:30AM	Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics (Zacks)
01:05AM	Decoding Viatris Inc (VTRS): A Strategic SWOT Insight (GuruFocus.com)
Aug-08-24 04:02PM	Analyst Report: Viatris Inc. (Morningstar Research) +6.51%
01:19PM	Midday stock movers: Warner Bros. sinks, Nvidia, Rivian, Eli Lilly up (TheStreet)
11:52AM	Why Viatris Stock Is Jumping Today (Motley Fool)
09:53AM	Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss (Zacks)
08:10AM	Viatris (VTRS) Q2 Earnings Surpass Estimates (Zacks)
07:08AM	Viatris: Q2 Earnings Snapshot (Associated Press Finance)
06:59AM	Viatris Reports Second Quarter Financial Results for 2024 (PR Newswire)
Aug-07-24 09:02AM	Viatris Inc (VTRS) Q2 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-06-24 06:04PM	Why Is Viatris Inc. (VTRS) the Best Dividend-Paying Stock to Buy Under $15? (Insider Monkey)
06:59AM	Viatris Announces Second Quarter 2024 Dividend (PR Newswire)
Aug-05-24 04:42PM	Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims (Reuters)
09:16AM	Seeking Clues to Viatris (VTRS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Aug-01-24 10:01AM	Earnings Preview: Viatris (VTRS) Q2 Earnings Expected to Decline (Zacks)
Jul-31-24 10:09AM	Viatris (VTRS) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-30-24 09:00AM	Aspargo Labs Publishes Results on First Oral Spray for Erectile Dysfunction (Exec Edge)
Jul-29-24 10:30AM	Viatris 2023 Sustainability Report: Empowering Healthcare Workers (ACCESSWIRE)
Jul-26-24 12:25PM	3 Surprisingly Underrated Stocks to Buy Right Now (Motley Fool)
Jul-25-24 01:00AM	Idorsia announces financial results for the first half 2024 (GlobeNewswire)
Jul-23-24 10:30AM	Viatris 2023 Sustainability Report: Building Access Through a Global and Flexible Supply Chain (ACCESSWIRE)
Jul-18-24 02:45PM	Viatris 2023 Sustainability Report: Our Strategy and Model for Sustainable Access to Medicine (ACCESSWIRE)
Jul-04-24 11:33AM	Viatris closes $3.37bn divestitures with OTC deal (Pharmaceutical Technology)
Jul-03-24 08:30AM	Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture (PR Newswire)
Jul-02-24 07:30AM	U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation (PR Newswire)
Jun-25-24 05:25PM	Viatris Named to TIME's World's Most Sustainable Companies 2024 List (ACCESSWIRE)
Jun-07-24 06:59AM	Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024 (PR Newswire)
Jun-04-24 06:59AM	Viatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
Jun-03-24 06:59AM	Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors (PR Newswire)
May-31-24 06:59AM	Viatris to Participate in the Jeffries Global Healthcare Conference (PR Newswire)
May-29-24 02:39AM	Insider Sale: Chief Legal Officer Brian Roman Sells 89,419 Shares of Viatris Inc (VTRS) (GuruFocus.com)
May-22-24 11:13AM	Viatris Inc's Dividend Analysis (GuruFocus.com)
May-21-24 06:30PM	Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale (ACCESSWIRE)
12:50AM	Idorsia announces financial results for the first quarter 2024 advancing the company with renewed vigor (GlobeNewswire)
May-10-24 02:32PM	Viatris Inc. (NASDAQ:VTRS) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:23PM	Viatris Inc. (VTRS) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic Shifts and ... (GuruFocus.com)
11:12AM	UBS Trims Viatris Price Target to $12 From $13, Maintains Neutral Rating (MT Newswires)
08:00AM	Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update (GlobeNewswire)
May-09-24 10:10PM	Q1 2024 Viatris Inc Earnings Call (Thomson Reuters StreetEvents)
04:23PM	Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast (Benzinga)
12:48PM	Analyst Report: Viatris Inc. (Morningstar Research)
11:56AM	VTRS Stock Earnings: Viatris Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
11:06AM	Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down (Zacks)
10:30AM	Viatris (VTRS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:24AM	Viagra maker Viatris misses revenue estimates on weak demand for older drugs (Reuters)
08:10AM	Viatris (VTRS) Q1 Earnings and Revenues Miss Estimates (Zacks)
07:30AM	Viatris' Q1 Adjusted Earnings, Revenue Decrease; 2024 Outlook Reduced (MT Newswires)
07:06AM	Viatris: Q1 Earnings Snapshot (Associated Press Finance)
06:59AM	Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges (PR Newswire)
May-08-24 11:19AM	Why Earnings Season Could Be Great for Viatris (VTRS) (Zacks)
May-06-24 09:50AM	Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store? (Zacks)
09:16AM	Viatris (VTRS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
May-02-24 05:00PM	Viatris to Participate in the BofA Securities 2024 Health Care Conference (PR Newswire)
10:01AM	Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Campbell Paul	See Remarks	Nov 11 '24	Sale	12.88	26,925	346,686	126,901	Nov 12 07:00 PM
Campbell Paul	Officer	Nov 11 '24	Proposed Sale	12.88	26,925	346,686		Nov 12 04:30 PM
Malik Rajiv	Director	Sep 12 '24	Sale	11.66	139,681	1,628,164	505,838	Sep 13 06:00 PM
Malik Rajiv	Director	Sep 12 '24	Sale	11.71	60,319	706,553	0	Sep 13 06:00 PM
Malik Rajiv	Director	Aug 30 '24	Sale	12.00	50,000	600,000	60,319	Aug 30 06:16 PM
Malik Rajiv	Director	Aug 28 '24	Sale	11.90	50,000	595,075	110,319	Aug 30 06:16 PM
Malik Rajiv	Director	Aug 21 '24	Sale	11.75	100,000	1,175,260	360,319	Aug 23 06:05 PM
Malik Rajiv	Director	Aug 23 '24	Sale	11.75	100,000	1,175,100	160,319	Aug 23 06:05 PM
Malik Rajiv	Director	Aug 22 '24	Sale	11.73	100,000	1,172,630	260,319	Aug 23 06:05 PM
Malik Rajiv	Director	Aug 20 '24	Proposed Sale	11.80	600,000	7,080,000		Aug 20 12:07 PM
Malik Rajiv	Director	Jun 14 '24	Sale	10.18	264,300	2,690,283	645,519	Jun 17 06:00 PM
Malik Rajiv	Director	Jun 13 '24	Sale	10.52	85,660	900,741	909,819	Jun 17 06:00 PM
Roman Brian	Chief Legal Officer	May 28 '24	Sale	10.38	89,419	928,429	67,723	May 28 06:00 PM
Mauro Anthony	See Remarks	Mar 13 '24	Sale	12.09	250,000	3,023,700	243,044	Mar 15 06:00 PM
Campbell Paul	See Remarks	Mar 04 '24	Option Exercise	0.00	19,427	0	185,132	Mar 05 08:36 PM
Campbell Paul	See Remarks	Mar 03 '24	Option Exercise	0.00	18,560	0	174,518	Mar 05 08:36 PM
Campbell Paul	See Remarks	Mar 02 '24	Option Exercise	0.00	90,297	0	180,524	Mar 05 08:36 PM
Campbell Paul	See Remarks	Mar 05 '24	Sale	12.33	24,353	300,272	153,826	Mar 05 08:36 PM
Mauro Anthony	See Remarks	Mar 04 '24	Option Exercise	0.00	39,784	0	507,164	Mar 05 08:35 PM
Mauro Anthony	See Remarks	Mar 03 '24	Option Exercise	0.00	37,835	0	485,243	Mar 05 08:35 PM
Mauro Anthony	See Remarks	Mar 02 '24	Option Exercise	0.00	192,630	0	499,154	Mar 05 08:35 PM
Roman Brian	Global General Counsel	Mar 04 '24	Option Exercise	0.00	18,650	0	163,817	Mar 05 08:29 PM
Roman Brian	Global General Counsel	Mar 03 '24	Option Exercise	0.00	17,598	0	153,541	Mar 05 08:29 PM
Roman Brian	Global General Counsel	Mar 02 '24	Option Exercise	0.00	84,277	0	158,905	Mar 05 08:29 PM
CORNWELL W DON	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	61,365	Mar 05 08:29 PM
FINNEY ELISHA W	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	18,855	Mar 05 08:25 PM
Groothuis Leo Frans	Director	Mar 03 '24	Option Exercise	0.00	22,484	0	22,154	Mar 05 08:24 PM
KORMAN HARRY	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	89,806	Mar 05 08:23 PM
KILTS JAMES M	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	117,445	Mar 05 08:22 PM
Lyons Dillon JoEllen	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	78,714	Mar 05 08:19 PM
Lyons Dillon JoEllen	Director	Mar 05 '24	Sale	12.36	20,000	247,200	58,714	Mar 05 08:19 PM
PARRISH MARK W	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	121,418	Mar 05 08:17 PM
MARK RICHARD A	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	72,333	Mar 05 08:14 PM
HIGGINS MELINA E	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	102,236	Mar 05 08:13 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 04 '24	Option Exercise	0.00	8,222	0	112,336	Mar 05 08:09 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 03 '24	Option Exercise	0.00	14,298	0	104,114	Mar 05 08:09 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 02 '24	Option Exercise	0.00	25,158	0	89,816	Mar 05 08:09 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 04 '24	Sale	12.51	21,532	269,314	90,804	Mar 05 08:09 PM
Malik Rajiv	President	Mar 04 '24	Option Exercise	0.00	89,514	0	1,027,249	Mar 05 08:09 PM
Malik Rajiv	President	Mar 03 '24	Option Exercise	0.00	85,788	0	978,180	Mar 05 08:09 PM
Malik Rajiv	President	Mar 02 '24	Option Exercise	0.00	433,416	0	1,008,849	Mar 05 08:09 PM
Smith Scott Andrew	Chief Executive Officer	Mar 03 '24	Option Exercise	0.00	140,727	0	135,829	Mar 05 08:01 PM
Cuneo Andrew	See Remarks	Mar 04 '24	Option Exercise	0.00	6,838	0	62,542	Mar 05 07:47 PM
Cuneo Andrew	See Remarks	Mar 03 '24	Option Exercise	0.00	13,199	0	61,485	Mar 05 07:47 PM
Cuneo Andrew	See Remarks	Mar 02 '24	Option Exercise	0.00	25,692	0	52,167	Mar 05 07:47 PM
Cuneo Andrew	See Remarks	Feb 23 '24	Sale	13.50	4,000	54,000	34,795	Feb 23 06:00 PM
Cuneo Andrew	See Remarks	Feb 15 '24	Sale	12.50	4,000	50,000	38,795	Feb 16 06:00 PM
Cuneo Andrew	See Remarks	Jan 04 '24	Sale	11.50	4,000	46,000	42,795	Jan 05 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Viatris Inc

Upgrade your FINVIZ experience